Blood Neoplasia
Publisher: Elsevier · ISSN 2950-3280 · 90 articles
- A long-term population-based study of lymphoplasmacytic lymphoma and Waldenström macroglobulinemia in Ontario, Canada
- Increased severe neurotoxicity and hospital stay in octogenarians receiving CAR T-cell therapy for large B-cell lymphoma
- Timing of response in patients with relapsed/refractory FLT3mut+ acute myeloid leukemia treated with gilteritinib
- Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML
- CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
- Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia
- A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine
- Prognostic implications of TET2 variant allele frequency in chronic myelomonocytic leukemia: a multicenter study
- TCL1A polymorphism predicts AML progression in myeloid neoplasms
- Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes
- Rosai-Dorfman disease: a 30-year institutional study of clinical features, treatment patterns, and outcomes
- Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP– but not Pola-R-CHP–treated patients with DLBCL
- CDK4/6i reverses MEIS2 inhibition of CRL4CRBN and promotes BCMA loss to enhance IMiD/CELMoD therapy in multiple myeloma
- Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia
- CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study
- Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events
- Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia
- Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors
- Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma
- IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience
- Kinetic BCR::ABL1 reduction by transcript types in frontline CML treatment: a GIMEMA LabNet CML network survey
- Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL
- GATA-3 identifies a distinct subset of T-PLL associated with skin involvement and CCR4 expression
- MCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia
- Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes
- Adkins J, Zhao C. Lineage switch in leukemia and lymphoma: case reports and molecular and cellular mechanisms. Blood Neoplasia. 2026;3(4):100265.
- PLK4 inhibition by CFI-400945 triggers polyploidy and synergistic apoptosis with venetoclax in TP53-mutant AML
- Circulating Multiple Myeloma Cell Kinetics and Genomic Profiling Predict Resistance to Targeted Immunotherapies
- Dual EZH2 & Histone Deacetylase Inhibition Suppresses Cell Viability in Down Syndrome Myeloid Leukemia by Depleting EZH2
- Actimab-A, a CD33-targeted Actinium-225 radioconjugate, drives potent mutation-agnostic efficacy in AML models